Home Alzheimer’s Disease Phase 3 Data Support Enfortumab Vedotin Benefit in Previously Treated Urothelial Carcinoma

Phase 3 Data Support Enfortumab Vedotin Benefit in Previously Treated Urothelial Carcinoma

Versus chemotherapy, enfortumab vedotin (Padcev) produced superior outcomes following platinum-based chemotherapy and PD-1/L1 inhibition in patients with advanced urothelial carcinoma, according to results of the phase 3 EV-301 clinical trial (NCT03474107) that were presented at the 2021 Genitourinary (GU) Cancers Symposium.1,2

These findings, which were simultaneously published in the New England Journal of Medicine, showed that efficacy benefits were observed in terms of progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) for enfortumab vedotin.

“Enfortumab vedotin is the first drug beyond chemotherapy and immunotherapy to show a significant survival advantage in previously treated advanced urothelial cancer,” said Thomas Powles, MBBS, MRCP, MD, in a presentation during the GU Cancers Symposium. “This is a big step in the right direction…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Treatment with PARP Inhibitors Increased Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia

Patients treated with PARP inhibitors saw an increased risk of myelodysplastic syndrome and acute myeloid leukemia (AML) versus patients treated with placebo, according to...

Salma Jabbour, MD, on Next Steps for the KEYNOTE-799 Study

The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed how she hopes the results of the KEYNOTE-799 study...

Recent Comments